EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial

Andrew M Novick, Tiffany M Love, Rachel L Johnson, Chloe E Page, Devin P Effinger, Danielle Sukenik, Kammy Bishop, Jacqueline Calderone, Jessica Scott, Heinrich Haller, Lauren Turow, Harmony Soffer und 6 weitere

Journal of Affective Disorders · 2027-01 · 417 · 122676

DOI: 10.1016/j.jad.2026.122676 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2027-01. Verfasst von Andrew M Novick und 17 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Behavior Innovation Center, Department of Psychiatry, University of Colorado School of Medicine, CU Anschutz Medical Campus, Aurora, CO, US…. Hauptthemen laut MEDLINE: Anhedonia, Psilocybin, Depressive Disorder, Treatment-Resistant, Major Depressive Disorder. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anhedonia is a core feature of major depressive disorder (MDD) that is frequently resistant to available treatments. Psilocybin's specific efficacy for anhedonia remains unclear. AIMS: To evaluate psilocybin's efficacy for anhedonia in treatment-resistant MDD. METHODS: In this randomized, double-blind, placebo-controlled trial, 20 participants with treatment-resistant MDD received psilocybin (25 mg or 1 mg) with psychological support. The primary outcome was change in the Dimensional Anhedonia Rating Scale (DARS) score at week 1; DARS change at week 8 was a secondary outcome. The Snaith-Hamilton Pleasure Scale (SHAPS) and Montgomery-Åsberg Depression Rating Scale (MADRS) were used as additional secondary outcome measures for anhedonia and overall depression severity, respectively. RESULTS: The primary outcome was not statistically significant: between-group difference in DARS change at week 1 was 11.2 (95% confidence interval [CI], -1.0 to 23.3; p = 0.073). At week 8, the secondary DARS outcome indicated greater improvement in anhedonia with 25 mg (difference, 14.7; 95% CI, 2.5 to 26.8; p = 0.018). SHAPS improvement favored 25 mg at week 1 (difference, -3.2; 95% CI, -6.1 to -0.3; p = 0.029), but not week 8 (-2.1; 95% CI, -4.9 to 0.9; p = 0.168). MADRS improvement favored 25 mg at weeks 1 (-11.9; 95% CI, -19.2 to -4.5; p = 0.002) and 8 (-11.6; 95% CI, -19.0 to -4.2; p = 0.002). CONCLUSIONS: Psilocybin 25 mg did not significantly improve anhedonia at the primary week 1 endpoint. However, improvements on secondary measures suggest potential benefits for anhedonia and depression severity that warrant confirmation in larger trials. CLINICAL TRIAL REGISTRATION: ClinicalTrials.govNCT06230757.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnhedoniaPsilocybinDepressive Disorder, Treatment-ResistantMajor Depressive DisorderHallucinogensHumansDouble-Blind MethodPilot ProjectsFemaleMaleAdultMiddle AgedPsychiatric Status Rating ScalesTreatment OutcomeCombined Modality Therapy

Stichwörter der Autor:innen

AnhedoniaPsilocybinRandomized controlled trialTreatment-resistant depression

Substanzen

PsilocybinHallucinogens

Autor:innen und Institutionen

  • Brain and Behavior Innovation Center, Department of Psychiatry, University of Colorado School of Medicine, CU Anschutz Medical Campus, Aurora, CO, USA. Electronic address: Andrew.m.novick@cuanschutz.edu.
  • Brain and Behavior Innovation Center, Department of Psychiatry, University of Colorado School of Medicine, CU Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Biostatistics and Informatics, Colorado School of Public Health, CU Anschutz Medical Campus, Aurora, CO, USA.
  • Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, CU Anschutz Medical Campus, Aurora, CO, USA.
  • Brain and Behavior Innovation Center, Department of Psychiatry, University of Colorado School of Medicine, CU Anschutz Medical Campus, Aurora, CO, USA; Department of Biostatistics and Informatics, Colorado School of Pub…

Förderung

  • NICHD NIH HHS
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute of Child Health and Human Development

Zitieren

APA

Novick, A. M., Love, T. M., Johnson, R. L., Page, C. E., Effinger, D. P., Sukenik, D., Bishop, K., Calderone, J., Scott, J., Haller, H., Turow, L., Soffer, H., Vonesh, L., Allen, M. H., Fischer, S. M., Sammel, M. D., Epperson, C. N., & Thompson, S. M. (2027). Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial. Journal of Affective Disorders, 417, 122676. https://doi.org/10.1016/j.jad.2026.122676

Vancouver

Novick AM, Love TM, Johnson RL, Page CE, Effinger DP, Sukenik D, et al. Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial. Journal of Affective Disorders. 2027;417:122676. doi:10.1016/j.jad.2026.122676

BibTeX
@article{Novick2027,
  author = {Novick, Andrew M and Love, Tiffany M and Johnson, Rachel L and Page, Chloe E and Effinger, Devin P and Sukenik, Danielle and Bishop, Kammy and Calderone, Jacqueline and Scott, Jessica and Haller, Heinrich and Turow, Lauren and Soffer, Harmony and Vonesh, Lily and Allen, Michael H and Fischer, Stacy M and Sammel, Mary D and Epperson, C Neill and Thompson, Scott M},
  title = {Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial},
  journal = {Journal of Affective Disorders},
  year = {2027},
  volume = {417},
  pages = {122676},
  doi = {10.1016/j.jad.2026.122676}
}
Kostenlos starten →